Cargando…
GPIIb/IIIa Receptor Antagonism Using Small Molecules Provides no Additive Long-Term Protection after Percutaneous Coronary Intervention as Compared to Clopidogrel Plus Aspirin
BACKGROUND: There is some controversy as to whether tirofiban or eptifibatide, two small anti-aggregating drugs (AAD), may reduce the incidence of composite ischemic events within one year in patients undergoing percutaneous coronary intervention (PCI) in the real clinical world. METHODS: We compare...
Autores principales: | Schiariti, Michele, Saladini, Angela, Papalia, Francesco, Grillo, Placido, Nesta, Cristina, Cuturello, Domenico, Missiroli, Bindo, Puddu, Paolo Emilio |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Bentham Open
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948151/ https://www.ncbi.nlm.nih.gov/pubmed/20922049 http://dx.doi.org/10.2174/1874192401004010151 |
Ejemplares similares
-
Is There Still a Role for Glycoprotein IIb/IIIa Antagonists in Acute Coronary Syndromes?
por: Iannetta, Loredana, et al.
Publicado: (2013) -
The GPIIb-IIIa defect of platelets in Glanzmann thrombasthenia
por: Nurden, Alan T.
Publicado: (2023) -
Biosynthesis and processing of platelet GPIIb-IIIa in human megakaryocytes
Publicado: (1987) -
Elevating local concentrations of GPIIb–IIIa antagonists counteracts platelet thrombus stability
por: Speich, Henry E., et al.
Publicado: (2012) -
Construction and expression of D-dimer and GPIIb/IIIa single-chain bispecific antibody
por: DAN, ZHAOKUI, et al.
Publicado: (2013)